Stay updated on TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.

Latest updates to the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as various new categories related to proteins and antibodies. Notably, previous references to certain diseases and antineoplastic agents have been removed.SummaryDifference5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to version v2.16.11, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
- Check36 days agoChange DetectedThe webpage has been updated with new clinical results regarding bladder cancer treatments, including confirmed objective response rates for both nivolumab monotherapy and the combination therapy with ipilimumab. Additionally, specific reporting dates for results have been added.SummaryDifference9%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check51 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.8%
Stay in the know with updates to TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.